Use of nasal steroids in managing allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 3 SUPPL., 1999, Pages

  LaForce, Craig ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b North Carolina Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE IRRITATION; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033014332     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70218-6     Document Type: Article

References (90)

1. Schleimer RP. Glucocorticosteroids. In: Middleton E, Reed C, Ellis E, editors. Allergy: principles and practice. St Louis (MO): Mosby; 1993. p. 893-925.
2. Lindqvist N, Andersson M, Bende M, Loth S, Pipkorn U. The clinical efficacy of budesonide in hay fever treatment is dependent on topical nasal application. Clin Exp Allergy 1989;19:71-6.
3. Rowland WC. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 1996;26(Suppl 3):18-22.
4. Barnes PJ. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 1996;97:159-68.
5. Townley RG, Suliaman F. The mechanism of action of corticesteroids in treating asthma. Ann Allergy 1987;58:1-8.
6. Schleimer RP. The mechanisms of antiinflammatory steroid action in allergic diseases. Annu Rev Pharmacol Toxicol 1985;25:381-412.
7. Pauwels R. Mode of action of corticosteroids in asthma and rhinitis. Clin Allergy 1986;16:281-8.
8. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14:436-41.
9. Connell JT. Quantitative intranasal pollen challenge: effect of daily pollen challenge, environmental exposure, and placebo challenge on the nasal membrane. J Allergy 1968;41:123-39.
10. Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol 1989;84:492-501.
11. Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ, Lichtenstein LM. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988;81:580-9.
12. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980;287:147-9.
13. Siegel SC. Topical corticosteroids in the management of rhinitis. In: Settipane GA, editor. Rhinitis. 2nd ed. Rhode Island: Oceanside Publications, Inc; 1991. p. 232.
14. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:1S-53S.
15. Rak S, Jacobson MR, Sudderick RM, Masuyama K, Juliusson S, Kay AB, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cel-lular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994;24:930-9.
16. Reed JC, Abidi AH, Alpers JD, Hoover RG, Robb RJ, Nowell PC. Effect of cyclosporin A and dexamethasone on interleukin-2 receptor gene expression. J Immunol 1986;137:150-4.
17. Masuyama K, Jacobson MR, Rak S, Meng Q, Sudderick R, Kay AB, et al. Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994;82:192-9.
18. van As A, Bronsky EA, Dockhorn RJ, Grossman J, Lumry W, Meltzer EO, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146-54.
19. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991;147:3490-5.
20. Kato M, Schleimer RP. Antiinflammatory steroids inhibit GM-CSF production by human lung tissue. Lung 1994;172:113-24.
21. Gomez E, Clague JE, Gatland D, Davies RJ. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells. BMJ 1988;296:1572-3.
22. Meltzer EO, Jalowayski AA, Field EA, Rogenes PR, Kral KM. Intranasal fluticasone propionate reduces histamine and tryptase in the mucosa of allergic rhinitis patients [abstract], J Allergy Clin Immunol 1993;91:298.
23. Guyre PM, Munck A. Glucocorticoid action on monocytes and macrophages. In: Schleimer RP, Claman HN, Oronsky AR, editors. Antiinflammatory steroid action. Basic and clinical aspects. New York: Academic Press; 1991. p. 199-225.
24. Hillas J, Booth RJ, Somerfield S, Morton R, Avery J, Wilson JD. A comparative trial of intra-nasal beclomethasone dipropionate and sodium cromoglycate in patients with chronic perennial rhinitis. Clin Allergy 1980;10:253-8.
25. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62:125-34.
26. Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989;83:627-33.
27. Bernstein DI, Creticos PS, Busse WW, Cohen R, Graft DF, Howland WC, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97:749-55.
28. Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-21.
29. Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995; 17:479-92.
30. Pelikan Z, de Vries K. Effects of some drugs applied topically to the nasal mucosa before nasal provocation tests with allergen. Acta Allergol 1974;29:337-53.
31. Mygind N, Johnsen NJ, Thomsen J. Intranasal allergen challenge during corticosteroid treatment. Clin Allergy 1977;7:69-74.
32. Vilsvik JS, Jenssen AO, Walstad R. The effect of beclomethasone dipropionate aerosol on allergen-induced nasal stenosis. Clin Allergy 1975;5:291-4.
33. Okuda M, Senba O. Effects of beclomethasone dipropionate nasal spray on subjective and objective findings in perennial allergic rhinitis. Clin Otolaryngol 1980;53:315-21.
34. Pipkorn U. Budesonide and nasal allergen challenge testing in man. Allergy 1982;37:129-34.
35. Andersson M, Andersson P, Pipkorn U. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity: relationship between treatment time and inhibitory effect. J Allergy Clin Immunol 1988;82:1019-26.
36. Baroody F, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Topical steroids inhibit antigen-induced nasal hyperreactivity to histamine [abstract]. J Allergy Clin Immunnol 1989;82:163.
37. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticoids. N Engl J Med 1987;316:1506-10.
38. Gronborg H, Bisgaard H, Romeling F, Mygind N. Early and late nasal symptom response to allergen challenge. Allergy 1993;48:87-93.
39. Linder A, Venge P, Deutschi H. Eosinophil cationic protein and myeloper-oxidase in nasal secretion as markers of inflammation in allergic rhinitis. Allergy 1987;42:583-90.
40. Garrelds IM, De Graaf-in Veld T, Nahori M, Vargaftig BB, van Wijk RG, Zijlstra FJ. Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis patients. Eur J Pharmacol 1995;275:295-300.
41. Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after allergen challenge during the pollen season. Int Arch Allergy Immunol 1997;114:185-92.
42. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:1900-6.
43. Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997;52(Suppl 36):29-32.
44. Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rijntjes E. Effect of 3 months nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 1995;50:204-9.
45. Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995;152:927-33.
46. Weido AJ, Reece LM, Alam R, Cook CK, Sim TC. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Ann Allergy Asthma Immunol 1996;77:407-15.
47. Naclerio RM, Adkinson NF Jr, Creticos PS, Baroody FM, Hamilton RG, Norman PS. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J Allergy Clin Immunol 1993; 92:717-21.
48. Pullerits T, Praks L, Sjostrand M, Rak S, Skoogh B, Lotvall J. An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season. J Allergy Clin Immunol 1997;100:601-5.
49. LaForce C, Davis V. Nasal septal perforation in patients using intranasal beclomethasone de(sic)propionate (BDP) [abstract], J Allergy Clin Immunol 1985;75(Suppl):186.
50. Naclerio RM, Mygind M. Intranasal steroids. In: Mygind N, Naclerio RM, editors. Allergic and non-allergic rhinitis: clinical aspects. Philadelphia: WB Saunders Co; 1993. p. 114-22.
51. Bircher AJ, Pelloni F, Messmer S, Muller D. Delayed hypersensitivity reactions to corticosteroids applied to mucous membranes. Br J Dermatol 1996;135:310-3.
52. Sorensen H, Mygind N, Pederson CB, Prytz S. Long term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol 1976; 182:260-2.
53. Orgel HA, Meltzer EO, Bierman CW, Bronsky E, Connell JT, Lieberman PL, et al. Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy. J Allergy Clin Immunol 1991;88:257-64.
54. Minshall E, Ghaffar O, Cameron L, O Brien F, Quinn H, Rowe-Jones J, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648-54.
55. Ratner P, van Bavel J, Gross G, Bynum L, Munshi A. New formulation of aqueous flunisolide nasal spray in the treatment of allergic rhinitis: comparative assessment of safety, tolerability, and efficacy. Allergy Asthma Proc 1996;17:149-56.
56. Munk ZM, LaForce C, Furst JA, Simpson B, Feiss G, Smith JA. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;77:277-81.
57. Norman PS, Winkenwerder WL, Agbayani BF, Migeon CJ. Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. J Allergy 1967;40:57-61.
58. Michels MI, Smith RE, Heimlich EM. Adrenal suppression and intranasally applied steroids. Ann Allergy 1967;25:569-74.
59. Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53:885-907.
60. Jeal W, Faulds D. Triamcinolone acetonide: a review of its pharmacolog-ic properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997;53:257-80.
61. Fraunfelder FT, Myer SM. Posterior subcapsular cataracts associated with nasal orinhalation corticosteroids. Am J Ophthalmol 1990;109:48990.
62. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.
63. LaForce CF, Dockhorn RJ, Findlay SR, Meltzer EO, Nathan RA, Stricker W, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 1994;38:145-52.
64. Seiner JC, Weber RW, Richmond GW, Stricker WE, Norton JD. Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Clin Ther 1995;17:1099-109.
65. Day JH, Buckeridge DL, Clark RH, Briscoe MP, Phillips R. A randomized, double-blind, placebo-controlled, antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996;97:1050-7.
66. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997; 19:27-38.
67. Juniper EF, Guyatt GH, O Byrne PM, Viveiros M. Aqueous beclomethasone dipropionate nasal spray: regular versus as required use in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990;86:380-6.
68. Juniper EF, Guyatt GH, Archer B, Ferrie PJ. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of as needed use. J Allergy Clin Immunol 1993;92:66-72.
69. Argenti D, Colligon I, Heald D, Ziemniak J. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide. J Clin Pharmacol 1994;34:854-8.
70. Falcoz C, Mackie AE, McDowall J, McRae J, Yogendran L, Ventresca GP, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:459P-60P.
71. Nasonex Product Monograph. Schering Corporation. Kenilworth, NJ. 1998.
72. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-5.
73. Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-13.
74. Ryrfeldt A, Andersson P, Edabaecker S, Toensson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(Suppl 122):86-95.
75. Edsbacker S, Andersson KE, Ryrfeldt A. Nasal bioavailability and sys-ternic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 1985;29:477-81.
76. Daley-Yates PT, McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drop (FP-drops) and aqueous nasal spray formulations (FPANS) [abstract]. Allergy 1998;53:158.
77. McDowall JE, Mackie AE, Ventresca GP, Bye A. Pharmacokinetics and bioavailability of intranasal fluticasone in humans. Clin Drug Invest 1997; 14:44-52.
78. Physicians desk reference. 52nd ed. Medical Economics Company; 1998. Nasarel( (flunisolide) Nasal Solution, 0.025%. Montvale, NJ. p. 889-91.
79. Physicians desk reference. 52nd ed. Medical Economics Company; 1998. Rhinocort Nasal Inhaler (budesonide), p. 572-4.
80. Falcoz C, Kirby SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur RespirJ 1996;9(Suppl 23):162S.
81. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998;132:472-7.
82. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.
83. Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715-9.
84. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-65.
85. Verberne AA, Frost C, Roorda RJ, van der Laag, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Pediatric Asthma Study Group. Am J Respir Crit Care Med 1997;156:688-95.
86. Rachelefsky GS, Chervinsky P, Meltzer EO, Morris RM, Seltzer JM, Skoner DP, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [Vancenase AQ (VNS)] on long-term growth in children [abstract]. J Allergy Clin Immunol 1998;101:S236.
87. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993;82:635-40.
88. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronnegard M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301-10.
89. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998;101:470-4.
90. Meltzer EO, Schatz M. Pharmacotherapy of rhinitis 1987 and beyond. Immunol Allergy Clin North Am 1987;7:57-91.